GeoVax Labs, Inc., a clinical-stage biotechnology company developing immunotherapies and multi-antigen vaccines against cancers and infectious diseases, announced relocations of its corporate headquarters and laboratory operations to new facilities in the Atlanta metropolitan area. The moves, scheduled for fourth quarter of 2025, will support GeoVax's continued growth, expanding pipeline, and preparation for product commercialization.
GeoVax's laboratory group is relocating to Science Square / Portal Innovations, located in midtown Atlanta. This state-of-the-art facility will provide the Company's R&D team with expanded access to modern laboratories and collaborative research environments designed to accelerate innovation and development activities. The Company's new corporate headquarters will be located at 1955 Lake Park Drive in Smyrna, Georgia, establishing a new hub for corporate operations and leadership activities.
These moves reflect a significant milestone in GeoVax's evolution, according to David Dodd, Chairman and Chief Executive Officer of GeoVax. By placing members of our R&D team in one of the most dynamic bio-research ecosystems in the Southeast, and by expanding our administrative base, we are positioning GeoVax for an accelerated next stage of growth. These facilities will support our broad and advancing pipeline, which includes our promising GEO-MVA program and multiple clinical trials in cancer therapy and infectious disease vaccines.
Eddie Lai, Director of Business Development, Atlanta Portal Innovations, expressed excitement about GeoVax joining Portal Atlanta at Science Square Labs. GeoVax brings a strong legacy of innovation rooted in the Southeast to the Portal Innovations ecosystem that includes 100+ innovative companies utilizing our sites across the country. As an innovation engine, Portal Innovations supports scientific companies including life sciences and biotech in all stages of development in both R&D and administrative capabilities, and GeoVax is a perfect addition to our growth right here in Atlanta.
The relocations underscore GeoVax's trajectory as a company focused on long-term growth, scientific advancement, and future commercialization opportunities. As the Company builds momentum with a deepening pipeline and strategic partnerships, its enhanced infrastructure will provide a strong foundation to meet global healthcare needs. For more information about the current status of our clinical trials and other updates, visit our website: https://www.geovax.com.
